Universal Ibogaine Inc. (TSXV:IBO)

Market Cap	6.26M
Revenue (ttm)	2.06M
Net Income (ttm)	-1.48M
Shares Out	312.86M
EPS (ttm)	-0.01
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	100,000
Average Volume	178,164
Open	0.0200
Previous Close	0.0200
Day's Range	0.0200 - 0.0200
52-Week Range	0.0050 - 0.0450
Beta	6.03
RSI	54.22
Earnings Date	Nov 28, 2025

About Universal Ibogaine

Universal Ibogaine Inc., a life sciences company, develops, acquires, and operates addiction treatment clinics in Canada. The company also undertakes planned clinical trial for research into the use of ibogaine for addiction treatment. Universal Ibogaine Inc. is headquartered in Calgary, Canada.

• Industry: Biotechnology
• Sector: Healthcare
• CEO: Nicholas Karos
• Country: Canada
• Stock Exchange: TSX Venture Exchange
• Ticker Symbol: IBO

Financial Performance

In 2024, Universal Ibogaine's revenue was 2.33 million, an increase of 126.32% compared to the previous year's 1.03 million. Losses were -2.05 million, -14.17% less than in 2023.